MC2 Therapeutics A/S appoints Anders D. Hove and Paul L. Berns to the Board of Directors
Copenhagen, July 18th, 2017
MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company, has appointed Dr. Anders D. Hove and Mr. Paul L. Berns to serve on the Board.
“On behalf of the Board it is my pleasure to welcome Dr. Hove and Mr. Berns as Directors of the Board. They have significant leadership experience in the pharmaceutical industry and are valuable contributors to our company as we evolve into a fully integrated commercial company” says Jesper J. Lange, President of MC2 Therapeutics.
Dr. Anders D. Hove, M.D.
Dr. Hove was most recently a managing general partner of Venrock Associates (“Venrock”), a venture capital firm, which he joined in January 2004 focusing on private and public biotech investments. In 2008, Dr. Hove was a founder of Venrock Healthcare Capital Partners, Venrock’s public fund focused on small capitalization biotech companies and late-stage private companies. Dr. Hove is a member of the board of directors of a number of public and private companies. He received a M.Sc. in Biotechnology Engineering from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from INSEAD, the Institut Européen d’Administration des Affaires in France.
Mr. Paul L Berns
Mr. Berns was appointed as President and Chief Executive Officer of Anacor Pharmaceuticals Inc. in 2014. He served as a Board member since 2012 and as Chairman since 2013. Anacor was acquired by Pfizer in June 2016. From March 2006 to September 2012, Mr. Berns served as President and Chief Executive Officer, and member of the board of directors, of Allos Therapeutics, Inc., which was acquired by Spectrum Pharmaceuticals, Inc. in September 2012. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in July 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, which was acquired by Abbott in 2001. From 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Mr. Berns has been a director of Jazz Pharmaceuticals, PLC since June 2010. Mr. Berns received a B.S. in Economics from the University of Wisconsin.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a privately held clinical-stage dermatology and eye care company. Using its proprietary PAD™ Technology – a new class of vehicle – MC2 Therapeutics is developing a pipeline of new topical drugs with designed for optimal patient compliance and superior real-life efficacy. We aim to provide a unique experience for patients and an attractive benefit to value proposition for payers.
For additional information on MC2 Therapeutics Group, please visit www.mc2therapeutics.com